Record_number,Author,Journal,Year,Vaccine,Vaccine_type,Manufacture,Group_ID,Group,Subgroup,Dose_level,Dose_concentration,Display_item,Time,Dosages,Measurement,N,Event,Risk
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, phase 1, adult",A,Lower,2,Table 2,7,Any,Solicited,24,11,46
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, phase 1, adult",A,Standard,4,Table 2,7,Any,Solicited,24,8,33
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, phase 1, adult",A,Higher,8,Table 2,7,Any,Solicited,24,11,46
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, phase 1, elderly",B,Lower,2,Table 3,7,Any,Solicited,24,1,4
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, phase 1, elderly",B,Standard,4,Table 3,7,Any,Solicited,24,6,25
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, phase 1, elderly",B,Higher,8,Table 3,7,Any,Solicited,24,5,21
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, phase 1, adult",A,Lower,2,Table 2,28,Any,Overall,24,12,50
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, phase 1, adult",A,Standard,4,Table 2,28,Any,Overall,24,11,46
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, phase 1, adult",A,Higher,8,Table 2,28,Any,Overall,24,11,46
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, phase 1, elderly",B,Lower,2,Table 3,28,Any,Overall,24,2,8
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, phase 1, elderly",B,Standard,4,Table 3,28,Any,Overall,24,7,29
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, phase 1, elderly",B,Higher,8,Table 3,28,Any,Overall,24,5,21
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, phase 1, adult",A,Lower,2,Table 2,7,Any,Local,24,NA,NA
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, phase 1, adult",A,Standard,4,Table 2,7,Any,Local,24,NA,NA
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, phase 1, adult",A,Higher,8,Table 2,7,Any,Local,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, phase 1, elderly",B,Lower,2,Table 3,7,Any,Local,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, phase 1, elderly",B,Standard,4,Table 3,7,Any,Local,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, phase 1, elderly",B,Higher,8,Table 3,7,Any,Local,24,NA,NA
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, phase 1, adult",A,Lower,2,Table 2,7,Any,Systemic,24,NA,NA
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, phase 1, adult",A,Standard,4,Table 2,7,Any,Systemic,24,NA,NA
15,"Xia, S",Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, phase 1, adult",A,Higher,8,Table 2,7,Any,Systemic,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, phase 1, elderly",B,Lower,2,Table 3,7,Any,Systemic,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, phase 1, elderly",B,Standard,4,Table 3,7,Any,Systemic,24,NA,NA
15,Xia. S,Lancet ID,2020,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, phase 1, elderly",B,Higher,8,Table 3,7,Any,Systemic,24,NA,NA
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, 3-5 yrs",A,Lower,2,Table 3,30,Full,Local,83,1,1.2
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, 3-5 yrs",A,Standard,4,Table 3,30,Full,Local,84,4,4.76
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, 3-5 yrs",A,Higher,8,Table 3,30,Full,Local,84,8,9.52
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, 6-12 yrs",B,Lower,2,Table 4,30,Full,Local,84,8,9.52
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, 6-12 yrs",B,Standard,4,Table 4,30,Full,Local,84,19,22.62
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, 6-12 yrs",B,Higher,8,Table 4,30,Full,Local,84,11,13.1
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A7,"2ug, 13-17 yrs",C,Lower,2,Table 5,30,Full,Local,84,10,11.9
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A8,"4ug, 13-17 yrs",C,Standard,4,Table 5,30,Full,Local,84,13,15.48
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A9,"8ug, 13-17 yrs",C,Higher,8,Table 5,30,Full,Local,84,6,7.14
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, 3-5 yrs",A,Lower,2,Table 3,30,Full,Systemic,83,14,16.87
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, 3-5 yrs",A,Standard,4,Table 3,30,Full,Systemic,84,22,26.19
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, 3-5 yrs",A,Higher,8,Table 3,30,Full,Systemic,84,28,33.33
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, 6-12 yrs",B,Lower,2,Table 4,30,Full,Systemic,84,6,7.14
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, 6-12 yrs",B,Standard,4,Table 4,30,Full,Systemic,84,6,7.14
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, 6-12 yrs",B,Higher,8,Table 4,30,Full,Systemic,84,14,16.67
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A7,"2ug, 13-17 yrs",C,Lower,2,Table 5,30,Full,Systemic,84,28,33.33
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A8,"4ug, 13-17 yrs",C,Standard,4,Table 5,30,Full,Systemic,84,17,20.24
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A9,"8ug, 13-17 yrs",C,Higher,8,Table 5,30,Full,Systemic,84,12,14.29
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A1,"2ug, 3-5 yrs",A,Lower,2,Table 3,30,Full,Overall,83,15,18.1
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A2,"4ug, 3-5 yrs",A,Standard,4,Table 3,30,Full,Overall,84,27,32.1
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A3,"8ug, 3-5 yrs",A,Higher,8,Table 3,30,Full,Overall,84,36,42.9
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A4,"2ug, 6-12 yrs",B,Lower,2,Table 4,30,Full,Overall,84,15,17.9
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A5,"4ug, 6-12 yrs",B,Standard,4,Table 4,30,Full,Overall,84,25,29.8
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A6,"8ug, 6-12 yrs",B,Higher,8,Table 4,30,Full,Overall,84,25,29.8
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A7,"2ug, 13-17 yrs",C,Lower,2,Table 5,30,Full,Overall,84,38,45.2
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A8,"4ug, 13-17 yrs",C,Standard,4,Table 5,30,Full,Overall,84,30,3.6
2382,"Xia, S",Lancet ID,2021,BBIBP-CorV,Inactivated,Sinopharm (Beijing),A9,"8ug, 13-17 yrs",C,Higher,8,Table 5,30,Full,Overall,84,18,21.4
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"Low-dose, phase 1",A,None,2.5,Table 2,7,Full,Local,24,5,20.8
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"Medium-dose, phase 1",A,None,5,Table 2,7,Full,Local,24,1,4.2
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"High-dose, phase 1",A,None,10,Table 2,7,Full,Local,24,6,25
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"Low-dose, phase 1",A,None,2.5,Table 2,7,Full,Systemic,24,0,0
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"Medium-dose, phase 1",A,None,5,Table 2,7,Full,Systemic,24,3,12.5
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"High-dose, phase 1",A,None,10,Table 2,7,Full,Systemic,24,1,4.2
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"Low-dose, phase 1",A,None,2.5,Table 2,28,Full,Overall,24,5,20.8
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"Medium-dose, phase 1",A,None,5,Table 2,28,Full,Overall,24,4,16.7
6,"Xia, S",JAMA,2020,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"High-dose, phase 1",A,None,10,Table 2,28,Full,Overall,24,6,25
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,7,Partial,Local,100,5,5
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,7,Partial,Local,100,5,5
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,7,Full,Local,100,2,2
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,7,Full,Local,100,1,1
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,7,Partial,Systemic,100,5,5
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,7,Partial,Systemic,100,14,14
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,7,Full,Systemic,100,5,5
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,7,Full,Systemic,100,1,1
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,28,Partial,Unsolicited,100,NA,NA
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,28,Partial,Unsolicited,100,NA,NA
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,"Low-dose, Algel-IMDG",A,Lower,3,Table 2/Table S2,28,Full,Unsolicited,100,NA,NA
42,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,"High-dose, Algel-IMDG",A,Standard,6,Table 2/Table S2,28,Full,Unsolicited,100,NA,NA
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,Low dose,A,Lower,3,Table 3/Text,7,Partial,Local,190,9,5
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,High dose,A,Standard,6,Table 3/Text,7,Partial,Local,190,8,4
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,Low dose,A,Lower,3,Table 3/Text,7,Full,Local,190,8,4
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,High dose,A,Standard,6,Table 3/Text,7,Full,Local,190,7,4
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,Low dose,A,Lower,3,Table 3/Text,7,Partial,Systemic,190,9,5
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,High dose,A,Standard,6,Table 3/Text,7,Partial,Systemic,190,14,7
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A1,Low dose,A,Lower,3,Table 3/Text,7,Any,Systemic,190,12,6
316,Ella. R,Lancet ID,2021,BBV152,Inactivated,Covaxin,A2,High dose,A,Standard,6,Table 3/Text,7,Any,Systemic,190,11,6
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A1,"Medium-dose, 14 days",A,Lower,100,Table 2,7,Any,Local,150,24,16
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A2,"High dose, 14 days",A,Standard,150,Table 2,7,Any,Local,150,27,18
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A3,"Medium-dose, 28 days",B,None,100,Table 2,7,Any,Local,150,22,14.7
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A4,"High dose, 28 days",B,None,150,Table 2,7,Any,Local,150,18,12
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A1,"Medium-dose, 14 days",A,Lower,100,Table 2,7,Any,Systemic,150,15,10
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A2,"High dose, 14 days",A,Standard,150,Table 2,7,Any,Systemic,150,20,13.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A3,"Medium-dose, 28 days",B,None,100,Table 2,7,Any,Systemic,150,20,13.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A4,"High dose, 28 days",B,None,150,Table 2,7,Any,Systemic,150,12,8
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A1,"Medium-dose, 14 days",A,Lower,100,Table 2,7,Any,Unsolicited,150,4,2.7
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A2,"High dose, 14 days",A,Standard,150,Table 2,7,Any,Unsolicited,150,2,1.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A3,"Medium-dose, 28 days",B,None,100,Table 2,7,Any,Unsolicited,150,11,7.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A4,"High dose, 28 days",B,None,150,Table 2,7,Any,Unsolicited,150,5,3.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A1,"Medium-dose, 14 days",A,Lower,100,Table 2,28,Any,Overall,150,36,24
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A2,"High dose, 14 days",A,Standard,150,Table 2,28,Any,Overall,150,41,27.3
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A3,"Medium-dose, 28 days",B,None,100,Table 2,28,Any,Overall,150,40,26.7
850,Che. Y,CID,2020,CAMS,Inactivated,Chinese Academy of Medical Sciences,A4,"High dose, 28 days",B,None,150,Table 2,28,Any,Overall,150,29,19.3
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Lower,1.5,appendix Table 2-4,7,Any,Local,57,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Standard,3,appendix Table 2-4,7,Any,Local,56,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,B,Lower,1.5,appendix Table 2-4,7,Any,Local,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,B,Standard,3,appendix Table 2-4,7,Any,Local,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A5,NA,C,Lower,1.5,appendix Table 2-4,7,Any,Local,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A6,NA,C,Standard,3,appendix Table 2-4,7,Any,Local,80,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Lower,1.5,appendix Table 2-4,7,Any,Systemic,57,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Standard,3,appendix Table 2-4,7,Any,Systemic,56,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,B,Lower,1.5,appendix Table 2-4,7,Any,Systemic,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,B,Standard,3,appendix Table 2-4,7,Any,Systemic,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A5,NA,C,Lower,1.5,appendix Table 2-4,7,Any,Systemic,81,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A6,NA,C,Standard,3,appendix Table 2-4,7,Any,Systemic,80,NA,NA
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Lower,1.5,appendix Table 2-4,7,Any,Solicited,57,12,21
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Standard,3,appendix Table 2-4,7,Any,Solicited,56,14,25
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,B,Lower,1.5,appendix Table 2-4,7,Any,Solicited,81,11,14
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,B,Standard,3,appendix Table 2-4,7,Any,Solicited,81,15,19
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A5,NA,C,Lower,1.5,appendix Table 2-4,7,Any,Solicited,81,28,35
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A6,NA,C,Standard,3,appendix Table 2-4,7,Any,Solicited,80,30,38
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Lower,1.5,appendix Table 2-4,28,Any,Unsolicited,57,2,4
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Standard,3,appendix Table 2-4,28,Any,Unsolicited,56,6,11
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,B,Lower,1.5,appendix Table 2-4,28,Any,Unsolicited,81,2,2
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,B,Standard,3,appendix Table 2-4,28,Any,Unsolicited,81,5,6
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A5,NA,C,Lower,1.5,appendix Table 2-4,28,Any,Unsolicited,81,7,9
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A6,NA,C,Standard,3,appendix Table 2-4,28,Any,Unsolicited,80,4,5
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Lower,1.5,appendix Table 2-4,28,Any,Overall,57,13,23
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Standard,3,appendix Table 2-4,28,Any,Overall,56,15,27
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,B,Lower,1.5,appendix Table 2-4,28,Any,Overall,81,12,15
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,B,Standard,3,appendix Table 2-4,28,Any,Overall,81,18,22
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A5,NA,C,Lower,1.5,appendix Table 2-4,28,Any,Overall,81,31,38
846,Han. B,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A6,NA,C,Standard,3,appendix Table 2-4,28,Any,Overall,80,30,38
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,A,Lower,1.5,Table 2,28,Any,Local,100,13,13
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1/A4,NA,A,Standard,3,Table 2,28,Any,Local,125,15,12
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2/A5,NA,A,Higher,6,Table 2,28,Any,Local,123,13,11
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,A,Lower,1.5,Table 2,28,Any,Systemic,100,10,10
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1/A4,NA,A,Standard,3,Table 2,28,Any,Systemic,125,13,10
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2/A5,NA,A,Higher,6,Table 2,28,Any,Systemic,123,18,15
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,A,Lower,1.5,Table 2,28,Any,Overall,100,20,20
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1/A4,NA,A,Standard,3,Table 2,28,Any,Overall,125,25,20
321,Wu. Z,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2/A5,NA,A,Higher,6,Table 2,28,Any,Overall,123,27,22
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,"Low dose, 14 days interval, phase 1",A,Standard,3,appendix Table 3-1,28,Any,Local,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,"High dose, 14 days interval, phase 1",A,Higher,6,appendix Table 3-1,28,Any,Local,24,5,20.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,14,Partial,Local,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,14,Partial,Local,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,28,Full,Local,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,28,Full,Local,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,"Low dose, 28 days interval, phase 1",B,Standard,3,appendix Table 3-3,28,Any,Local,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,"High dose, 28 days interval, phase 1",B,Higher,6,appendix Table 3-3,28,Any,Local,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Partial,Local,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Partial,Local,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Full,Local,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Full,Local,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,"Low dose, 14 days interval, phase 2",C,Standard,3,appendix Table 3-5,28,Any,Local,120,28,23.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,"High dose, 14 days interval, phase 2",C,Higher,6,appendix Table 3-5,28,Any,Local,120,33,27.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,14,Partial,Local,120,13,10.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,14,Partial,Local,120,21,17.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,28,Full,Local,120,17,14.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,28,Full,Local,120,15,12.6
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,"Low dose, 28 days interval, phase 2",D,Standard,3,appendix Table 3-7,28,Any,Local,120,12,10
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,"High dose, 28 days interval, phase 2",D,Higher,6,appendix Table 3-7,28,Any,Local,120,16,13.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Partial,Local,120,9,7.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Partial,Local,120,15,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Full,Local,117,3,2.6
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Full,Local,118,8,6.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,"Low dose, 14 days interval, phase 1",A,Standard,3,appendix Table 3-1,28,Any,Systemic,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,"High dose, 14 days interval, phase 1",A,Higher,6,appendix Table 3-1,28,Any,Systemic,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,14,Partial,Systemic,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,14,Partial,Systemic,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,28,Full,Systemic,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,28,Full,Systemic,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,"Low dose, 28 days interval, phase 1",B,Standard,3,appendix Table 3-3,28,Any,Systemic,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,"High dose, 28 days interval, phase 1",B,Higher,6,appendix Table 3-3,28,Any,Systemic,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Partial,Systemic,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Partial,Systemic,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Full,Systemic,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Full,Systemic,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,"Low dose, 14 days interval, phase 2",C,Standard,3,appendix Table 3-5,28,Any,Systemic,120,19,15.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,"High dose, 14 days interval, phase 2",C,Higher,6,appendix Table 3-5,28,Any,Systemic,120,16,13.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,14,Partial,Systemic,120,15,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,14,Partial,Systemic,120,13,10.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,28,Full,Systemic,120,5,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,28,Full,Systemic,120,6,5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,"Low dose, 28 days interval, phase 2",D,Standard,3,appendix Table 3-7,28,Any,Systemic,120,14,11.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,"High dose, 28 days interval, phase 2",D,Higher,6,appendix Table 3-7,28,Any,Systemic,120,12,10
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Partial,Systemic,120,14,11.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Partial,Systemic,120,10,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Full,Systemic,117,4,3.4
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Full,Systemic,118,3,2.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,"Low dose, 14 days interval, phase 1",A,Standard,3,appendix Table 3-1,28,Any,Solicited,24,6,25
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,"High dose, 14 days interval, phase 1",A,Higher,6,appendix Table 3-1,28,Any,Solicited,24,9,37.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,14,Partial,Solicited,24,6,25
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,14,Partial,Solicited,24,6,25
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,28,Full,Solicited,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,28,Full,Solicited,24,5,20.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,"Low dose, 28 days interval, phase 1",B,Standard,3,appendix Table 3-3,28,Any,Solicited,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,"High dose, 28 days interval, phase 1",B,Higher,6,appendix Table 3-3,28,Any,Solicited,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Partial,Solicited,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Partial,Solicited,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Full,Solicited,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Full,Solicited,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,"Low dose, 14 days interval, phase 2",C,Standard,3,appendix Table 3-5,28,Any,Solicited,120,39,32.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,"High dose, 14 days interval, phase 2",C,Higher,6,appendix Table 3-5,28,Any,Solicited,120,40,33.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,14,Partial,Solicited,120,23,19.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,14,Partial,Solicited,120,27,22.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,28,Full,Solicited,120,19,15.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,28,Full,Solicited,120,20,16.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,"Low dose, 28 days interval, phase 2",D,Standard,3,appendix Table 3-7,28,Any,Solicited,120,23,19.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,"High dose, 28 days interval, phase 2",D,Higher,6,appendix Table 3-7,28,Any,Solicited,120,23,19.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Partial,Solicited,120,22,18.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Partial,Solicited,120,21,17.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Full,Solicited,117,7,6
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Full,Solicited,118,10,8.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,"Low dose, 14 days interval, phase 1",A,Standard,3,appendix Table 3-1,28,Any,Unsolicited,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,"High dose, 14 days interval, phase 1",A,Higher,6,appendix Table 3-1,28,Any,Unsolicited,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,14,Partial,Unsolicited,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,14,Partial,Unsolicited,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,28,Full,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,28,Full,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,"Low dose, 28 days interval, phase 1",B,Standard,3,appendix Table 3-3,28,Any,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,"High dose, 28 days interval, phase 1",B,Higher,6,appendix Table 3-3,28,Any,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Partial,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Partial,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Full,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Full,Unsolicited,24,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,"Low dose, 14 days interval, phase 2",C,Standard,3,appendix Table 3-5,28,Any,Unsolicited,120,3,2.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,"High dose, 14 days interval, phase 2",C,Higher,6,appendix Table 3-5,28,Any,Unsolicited,120,3,2.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,14,Partial,Unsolicited,120,2,1.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,14,Partial,Unsolicited,120,3,2.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,28,Full,Unsolicited,120,1,0.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,28,Full,Unsolicited,120,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,"Low dose, 28 days interval, phase 2",D,Standard,3,appendix Table 3-7,28,Any,Unsolicited,120,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,"High dose, 28 days interval, phase 2",D,Higher,6,appendix Table 3-7,28,Any,Unsolicited,120,1,0.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Partial,Unsolicited,120,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Partial,Unsolicited,120,1,0.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Full,Unsolicited,117,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Full,Unsolicited,118,0,0
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,"Low dose, 14 days interval, phase 1",A,Standard,3,appendix Table 3-1,28,Any,Overall,24,7,29.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,"High dose, 14 days interval, phase 1",A,Higher,6,appendix Table 3-1,28,Any,Overall,24,9,37.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,14,Partial,Overall,24,7,29.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,14,Partial,Overall,24,6,25
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A1,NA,A,Standard,3,appendix Table 3-2,28,Full,Overall,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A2,NA,A,Higher,6,appendix Table 3-2,28,Full,Overall,24,5,20.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,"Low dose, 28 days interval, phase 1",B,Standard,3,appendix Table 3-3,28,Any,Overall,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,"High dose, 28 days interval, phase 1",B,Higher,6,appendix Table 3-3,28,Any,Overall,24,4,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Partial,Overall,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Partial,Overall,24,3,12.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B1,NA,B,Standard,3,appendix Table 3-4,28,Full,Overall,24,2,8.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B2,NA,B,Higher,6,appendix Table 3-4,28,Full,Overall,24,1,4.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,"Low dose, 14 days interval, phase 2",C,Standard,3,appendix Table 3-5,28,Any,Overall,120,40,33.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,"High dose, 14 days interval, phase 2",C,Higher,6,appendix Table 3-5,28,Any,Overall,120,42,35
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,14,Partial,Overall,120,24,20
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,14,Partial,Overall,120,29,24.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A3,NA,C,Standard,3,appendix Table 3-6,28,Full,Overall,120,20,16.7
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,A4,NA,C,Higher,6,appendix Table 3-6,28,Full,Overall,120,20,16.8
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,"Low dose, 28 days interval, phase 2",D,Standard,3,appendix Table 3-7,28,Any,Overall,120,23,19.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,"High dose, 28 days interval, phase 2",D,Higher,6,appendix Table 3-7,28,Any,Overall,120,23,19.2
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Partial,Overall,120,22,18.3
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Partial,Overall,120,21,17.5
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B3,NA,D,Standard,3,appendix Table 3-8,28,Full,Overall,117,7,6
30,Zhang. Y,Lancet ID,2021,CoronaVac,Inactivated,Sinovac,B4,NA,D,Higher,6,appendix Table 3-8,28,Full,Overall,118,10,8.5
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A1,"Low dose, phase 1",A,None,5,Table 2,28,Any,Local,24,4,17
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A2,"High dose, phase 1",A,None,10,Table 2,28,Any,Local,24,4,17
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A3,"Low dose, 14 days, phase 2",B,None,5,Table 2,28,Any,Local,100,11,11
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A4,"High dose, 14 days, phase 2",B,None,10,Table 2,28,Any,Local,100,8,8
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B1,"Low dose, 28 days, phase 2",C,Standard,5,Table 2,28,Any,Local,100,16,16
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B2,"High dose, 28 days, phase 2",C,Higher,10,Table 2,28,Any,Local,100,18,18
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A1,"Low dose, phase 1",A,None,5,Table 2,28,Any,Systemic,24,2,8
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A2,"High dose, phase 1",A,None,10,Table 2,28,Any,Systemic,24,1,4
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A3,"Low dose, 14 days, phase 2",B,None,5,Table 2,28,Any,Systemic,100,6,6
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A4,"High dose, 14 days, phase 2",B,None,10,Table 2,28,Any,Systemic,100,11,11
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B1,"Low dose, 28 days, phase 2",C,Standard,5,Table 2,28,Any,Systemic,100,6,6
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B2,"High dose, 28 days, phase 2",C,Higher,10,Table 2,28,Any,Systemic,100,10,10
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A1,"Low dose, phase 1",A,None,5,Table 2,28,Any,Unsolicited,24,7,29
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A2,"High dose, phase 1",A,None,10,Table 2,28,Any,Unsolicited,24,3,13
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A3,"Low dose, 14 days, phase 2",B,None,5,Table 2,28,Any,Unsolicited,100,0,0
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A4,"High dose, 14 days, phase 2",B,None,10,Table 2,28,Any,Unsolicited,100,0,0
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B1,"Low dose, 28 days, phase 2",C,Standard,5,Table 2,28,Any,Unsolicited,100,0,0
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B2,"High dose, 28 days, phase 2",C,Higher,10,Table 2,28,Any,Unsolicited,100,0,0
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A1,"Low dose, phase 1",A,None,5,Table 2,28,Any,Overall,24,13,54
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A2,"High dose, phase 1",A,None,10,Table 2,28,Any,Overall,24,11,46
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A3,"Low dose, 14 days, phase 2",B,None,5,Table 2,28,Any,Overall,100,16,16
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,A4,"High dose, 14 days, phase 2",B,None,10,Table 2,28,Any,Overall,100,19,19
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B1,"Low dose, 28 days, phase 2",C,Standard,5,Table 2,28,Any,Overall,100,25,25
312,Pan. H. X,Chinese Medical Journal,2021,KCONVAC,Inactivated,Minhai BioTech,B2,"High dose, 28 days, phase 2",C,Higher,10,Table 2,28,Any,Overall,100,26,26
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"3 low doses, aged 18 to 59",A,None,2.5,Table 2,7,Any,Local,84,11,13.1
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"3 middle doses, aged 18 to 59",A,None,5,Table 2,7,Any,Local,84,15,17.9
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"3 high doses, aged 18 to 59",A,None,10,Table 2,7,Any,Local,84,21,25
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A4,"3 low doses, aged 60 and above",B,None,2.5,Table 2,7,Any,Local,84,2,2.4
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A5,"3 middle doses, aged 60 and above",B,None,5,Table 2,7,Any,Local,84,11,13.1
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A6,"3 high doses, aged 60 and above",B,None,10,Table 2,7,Any,Local,84,3,3.6
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"3 low doses, aged 18 to 59",A,None,2.5,Table 2,7,Any,Systemic,84,3,3.6
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"3 middle doses, aged 18 to 59",A,None,5,Table 2,7,Any,Systemic,84,4,4.8
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"3 high doses, aged 18 to 59",A,None,10,Table 2,7,Any,Systemic,84,1,1.2
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A4,"3 low doses, aged 60 and above",B,None,2.5,Table 2,7,Any,Systemic,84,2,2.4
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A5,"3 middle doses, aged 60 and above",B,None,5,Table 2,7,Any,Systemic,84,4,4.8
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A6,"3 high doses, aged 60 and above",B,None,10,Table 2,7,Any,Systemic,84,4,4.8
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A1,"3 low doses, aged 18 to 59",A,None,2.5,Table 2,7,Any,Unsolicited,84,0,0
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A2,"3 middle doses, aged 18 to 59",A,None,5,Table 2,7,Any,Unsolicited,84,0,0
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A3,"3 high doses, aged 18 to 59",A,None,10,Table 2,7,Any,Unsolicited,84,0,0
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A4,"3 low doses, aged 60 and above",B,None,2.5,Table 2,7,Any,Unsolicited,84,0,0
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A5,"3 middle doses, aged 60 and above",B,None,5,Table 2,7,Any,Unsolicited,84,0,0
977,Guo. W,EClinicalMedicine,2021,Sinopharm (Wuhan),Inactivated,Sinopharm (Wuhan),A6,"3 high doses, aged 60 and above",B,None,10,Table 2,7,Any,Unsolicited,84,0,0
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Partial,Local,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Partial,Local,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Partial,Local,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Partial,Local,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Partial,Local,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Partial,Local,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Partial,Local,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Partial,Local,31,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Partial,Systemic,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Partial,Systemic,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Partial,Systemic,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Partial,Systemic,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Partial,Systemic,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Partial,Systemic,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Partial,Systemic,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Partial,Systemic,31,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,21,Partial,Unsolicited,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,21,Partial,Unsolicited,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,21,Partial,Unsolicited,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,21,Partial,Unsolicited,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,21,Partial,Unsolicited,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,21,Partial,Unsolicited,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,21,Partial,Unsolicited,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,21,Partial,Unsolicited,31,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Full,Local,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Full,Local,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Full,Local,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Full,Local,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Full,Local,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Full,Local,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Full,Local,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Full,Local,31,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Full,Systemic,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Full,Systemic,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,7,Full,Systemic,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,7,Full,Systemic,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Full,Systemic,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Full,Systemic,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,7,Full,Systemic,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,7,Full,Systemic,31,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A1,"Low-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,21,Full,Unsolicited,16,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B1,"Low-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,21,Full,Unsolicited,51,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A2,"High-dose plus AF03, aged 18 to 49",A,None,1.3,Table S6,21,Full,Unsolicited,17,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B2,"High-dose plus AS03, aged 18 to 49",B,None,2.6,Table S6,21,Full,Unsolicited,54,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A3,"Low-dose plus AF03, aged above 50",C,None,1.3,Table S6,21,Full,Unsolicited,10,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B3,"Low-dose plus AS03, aged above 50",D,None,2.6,Table S6,21,Full,Unsolicited,28,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,A4,"High-dose plus AF03, aged above 50",C,None,1.3,Table S6,21,Full,Unsolicited,9,NA,NA
906,Goepfert. P. A,Lancet ID,2021,CoV2 preS dTM,Recombinant,Sanofi/GSK,B4,"High-dose plus AS03, aged above 50",D,None,2.6,Table S6,21,Full,Unsolicited,31,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,"sup Table 2.2, 2.3",7,Partial,Local,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,"sup Table 2.2, 2.3",7,Partial,Local,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,"sup Table 2.2, 2.3",7,Partial,Local,48,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,"sup Table 2.2, 2.3",7,Full,Local,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,"sup Table 2.2, 2.3",7,Full,Local,22,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,"sup Table 2.2, 2.3",7,Full,Local,21,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,"sup Table 2.2, 2.3",7,Partial,Systemic,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,"sup Table 2.2, 2.3",7,Partial,Systemic,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,"sup Table 2.2, 2.3",7,Partial,Systemic,48,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,"sup Table 2.2, 2.3",7,Full,Systemic,24,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,"sup Table 2.2, 2.3",7,Full,Systemic,22,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,"sup Table 2.2, 2.3",7,Full,Systemic,21,NA,NA
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,Text,NA,Any,Solicited,24,22,92
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,Text,NA,Any,Solicited,24,23,96
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,Text,NA,Any,Solicited,24,21,88
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A1,NA,A,None,5,sup Table 2.1,NA,Any,Unsolicited,24,13,54.2
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A2,NA,A,None,15,sup Table 2.1,NA,Any,Unsolicited,24,7,29.2
812,Chappell. K. J,The Lancet,2021,Sclamp,Recombinant,Queensland,A3,NA,A,None,45,sup Table 2.1,NA,Any,Unsolicited,24,7,29.2
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Any,Local,15,13,86.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Any,Local,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Any,Local,15,11,73.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Partial,Local,15,11,73.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Partial,Local,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Partial,Local,15,11,73.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Full,Local,15,10,66.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Full,Local,15,8,53.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Full,Local,15,9,60
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Any,Systemic,15,4,26.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Any,Systemic,15,6,40
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Any,Systemic,15,6,40
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Partial,Systemic,15,2,13.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Partial,Systemic,15,5,33.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Partial,Systemic,15,6,40
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Full,Systemic,15,4,26.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Full,Systemic,15,1,6.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Full,Systemic,15,4,26.7
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Any,Solicited,15,14,93.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Any,Solicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Any,Solicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Partial,Solicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Partial,Solicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Partial,Solicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,7,Full,Solicited,15,11,73.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,7,Full,Solicited,15,8,53.3
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,7,Full,Solicited,15,9,60
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A1,Low dose,A,Lower,5,appendix Table S2,28,Any,Unsolicited,15,12,80
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A2,Medium dose,A,Standard,15,appendix Table S2,28,Any,Unsolicited,15,9,60
926,Hsieh. S.M,EClinicalMedicine,2021,MVC-COV1901,Recombinant,Medigen,A3,High dose,A,Higher,25,appendix Table S2,28,Any,Unsolicited,15,11,73.3
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A1,"Group B, young",A,Standard,5,appendix Table F,NA,Partial,Local,139,87,62.6
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A2,"Group C, young",B,None,5,appendix Table F,NA,Partial,Local,138,92,66.7
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A3,"Group D, young",A,Higher,25,appendix Table F,NA,Partial,Local,139,104,74.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A4,"Group E, young",B,None,25,appendix Table F,NA,Partial,Local,136,105,77.2
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A5,"Group B, elderly",C,Standard,5,appendix Table F,NA,Partial,Local,114,44,38.6
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A6,"Group C, elderly",D,None,5,appendix Table F,NA,Partial,Local,117,43,36.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A7,"Group D, elderly",C,Higher,25,appendix Table F,NA,Partial,Local,113,50,44.2
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A8,"Group E, elderly",D,None,25,appendix Table F,NA,Partial,Local,117,70,59.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A1,"Group B, young",A,Standard,5,appendix Table G,NA,Full,Local,137,105,76.6
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A2,"Group C, young",B,None,5,appendix Table G,NA,Full,Local,136,19,14
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A3,"Group D, young",A,Higher,25,appendix Table G,NA,Full,Local,137,126,92
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A4,"Group E, young",B,None,25,appendix Table G,NA,Full,Local,137,9,7.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A5,"Group B, elderly",C,Standard,5,appendix Table G,NA,Full,Local,113,70,61.9
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A6,"Group C, elderly",D,None,5,appendix Table G,NA,Full,Local,113,8,7.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A7,"Group D, elderly",C,Higher,25,appendix Table G,NA,Full,Local,110,74,67.3
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A8,"Group E, elderly",D,None,25,appendix Table G,NA,Full,Local,109,11,10.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A1,"Group B, young",A,Standard,5,appendix Table F,NA,Partial,Systemic,139,68,48.9
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A2,"Group C, young",B,None,5,appendix Table F,NA,Partial,Systemic,138,66,47.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A3,"Group D, young",A,Higher,25,appendix Table F,NA,Partial,Systemic,139,79,56.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A4,"Group E, young",B,None,25,appendix Table F,NA,Partial,Systemic,136,60,44.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A5,"Group B, elderly",C,Standard,5,appendix Table F,NA,Partial,Systemic,114,44,37.9
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A6,"Group C, elderly",D,None,5,appendix Table F,NA,Partial,Systemic,117,36,30.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A7,"Group D, elderly",C,Higher,25,appendix Table F,NA,Partial,Systemic,113,33,29.2
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A8,"Group E, elderly",D,None,25,appendix Table F,NA,Partial,Systemic,117,40,34.2
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A1,"Group B, young",A,Standard,5,appendix Table G,NA,Full,Systemic,137,88,64.2
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A2,"Group C, young",B,None,5,appendix Table G,NA,Full,Systemic,136,46,33.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A3,"Group D, young",A,Higher,25,appendix Table G,NA,Full,Systemic,137,101,73.7
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A4,"Group E, young",B,None,25,appendix Table G,NA,Full,Systemic,137,29,22.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A5,"Group B, elderly",C,Standard,5,appendix Table G,NA,Full,Systemic,113,44,38.9
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A6,"Group C, elderly",D,None,5,appendix Table G,NA,Full,Systemic,113,25,22.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A7,"Group D, elderly",C,Higher,25,appendix Table G,NA,Full,Systemic,110,56,50.9
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A8,"Group E, elderly",D,None,25,appendix Table G,NA,Full,Systemic,109,22,20.4
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A1/A5,Group B,AC,Standard,5,appendix Table F,35,Any,Unsolicited,258,51,19.8
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A2/A6,Group C,BD,None,5,appendix Table F,35,Any,Unsolicited,256,35,13.7
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A3/A7,Group D,AC,Higher,25,appendix Table F,35,Any,Unsolicited,259,52,20.1
1582,Formica. N,PLoS Med,2021,NVX-CoV2373,Recombinant,Novavax,A4/A8,Group E,BD,None,25,appendix Table F,35,Any,Unsolicited,255,43,16.9
11,Keech. C,NEw England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A1,Group C,A,Standard,5,appendix Table S7,14,Partial,Local,26,18,69.2
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A2,Group D,A,Higher,25,appendix Table S7,14,Partial,Local,25,15,60
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A1,Group C,A,Standard,5,appendix Table S7,14,Full,Local,26,24,92.3
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A2,Group D,A,Higher,25,appendix Table S7,14,Full,Local,24,19,79.2
11,Keech. C,NEw England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A1,Group C,A,Standard,5,appendix Table S7,14,Partial,Systemic,26,12,46.2
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A2,Group D,A,Higher,25,appendix Table S7,14,Partial,Systemic,25,14,56
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A1,Group C,A,Standard,5,appendix Table S7,14,Full,Systemic,26,17,65.4
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A2,Group D,A,Higher,25,appendix Table S7,14,Full,Systemic,24,18,75
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A1,Group C,A,Standard,5,Text,14,Any,Unsolicited,NA,NA,NA
11,Keech. C,New England Journal of Medicine,2020,NVX-CoV2373,Recombinant,Novavax,A2,Group D,A,Higher,25,Text,14,Any,Unsolicited,NA,NA,NA
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A1/A4,NA,A,Lower,3,Figure 2,7,Partial,Local,16,7,43.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A2/A5,NA,A,Standard,9,Figure 2,7,Partial,Local,16,8,50
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A3/A6,NA,A,Higher,30,Figure 2,7,Partial,Local,16,9,56.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B1/B4,NA,B,Lower,3,Figure 2,7,Partial,Local,16,1,6.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B2/B5,NA,B,Standard,9,Figure 2,7,Partial,Local,16,5,31.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B3/B6,NA,B,Standard,30,Figure 2,7,Partial,Local,16,7,43.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A1/A4,NA,A,Lower,3,Figure 2,7,Full,Local,16,8,50
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A2/A5,NA,A,Standard,9,Figure 2,7,Full,Local,16,11,68.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A3/A6,NA,A,Higher,30,Figure 2,7,Full,Local,16,8,50
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B1/B4,NA,B,Lower,3,Figure 2,7,Full,Local,16,2,12.5
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B2/B5,NA,B,Standard,9,Figure 2,7,Full,Local,15,5,33.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B3/B6,NA,B,Standard,30,Figure 2,7,Full,Local,16,7,43.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A1/A4,NA,A,Lower,3,Figure 2,7,Partial,Systemic,16,6,37.5
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A2/A5,NA,A,Standard,9,Figure 2,7,Partial,Systemic,16,4,25
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A3/A6,NA,A,Higher,30,Figure 2,7,Partial,Systemic,16,6,37.5
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B1/B4,NA,B,Lower,3,Figure 2,7,Partial,Systemic,16,4,25
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B2/B5,NA,B,Standard,9,Figure 2,7,Partial,Systemic,16,6,37.5
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B3/B6,NA,B,Standard,30,Figure 2,7,Partial,Systemic,16,3,18.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A1/A4,NA,A,Lower,3,Figure 2,7,Full,Systemic,16,8,50
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A2/A5,NA,A,Standard,9,Figure 2,7,Full,Systemic,16,9,56.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,A3/A6,NA,A,Higher,30,Figure 2,7,Full,Systemic,16,7,43.8
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B1/B4,NA,B,Lower,3,Figure 2,7,Full,Systemic,16,4,25
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B2/B5,NA,B,Standard,9,Figure 2,7,Full,Systemic,15,2,13.3
285,Richmond. P,Lancet,2021,SCB-2019,Recombinant,Clover,B3/B6,NA,B,Standard,30,Figure 2,7,Full,Systemic,16,5,31.3
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A1,"Low-dose, phase 1, 2 doses, 28 days, adult",A,None,20,Table 2,7,Any,Local,24,3,13
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A2,"High-dose, phase 1, 2 doses, 28 days, adult",A,None,40,Table 2,7,Any,Local,24,3,13
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A3,"Low-dose, phase 1, 2 doses, 28 days, elderly",B,None,20,Table 2,7,Any,Local,18,1,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A4,"High-dose, phase 1, 2 doses, 28 days, elderly",B,None,40,Table 2,7,Any,Local,18,2,11
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C1,"Low-dose, phase 2, 2 doses, 21 days, adult",C,None,20,Table 3,7,Any,Local,100,6,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C2,"High-dose, phase 2, 2 doses, 21 days, adult",C,None,40,Table 3,7,Any,Local,100,16,16
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B3,"Low-dose, phase 2, 3 doses, 28 days, adult",D,Lower,20,Table 3,7,Any,Local,100,13,13
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B4,"High-dose, phase 2, 3 doses, 28 days, adult",D,Standard,40,Table 3,7,Any,Local,100,25,25
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C3,"Low-dose, phase 2, 2 doses, 21 days, elderly",E,None,20,Table 3,7,Any,Local,100,4,4
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C4,"High-dose, phase 2, 2 doses, 21 days, elderly",E,None,40,Table 3,7,Any,Local,100,9,9
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B5,"Low-dose, phase 2, 3 doses, 28 days, elderly",F,Lower,20,Table 3,7,Any,Local,100,10,10
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B6,"High-dose, phase 2, 3 doses, 28 days, elderly",F,Standard,40,Table 3,7,Any,Local,100,8,8
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A1,"Low-dose, phase 1, 2 doses, 28 days, adult",A,None,20,Table 2,7,Any,Systemic,24,3,13
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A2,"High-dose, phase 1, 2 doses, 28 days, adult",A,None,40,Table 2,7,Any,Systemic,24,5,21
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A3,"Low-dose, phase 1, 2 doses, 28 days, elderly",B,None,20,Table 2,7,Any,Systemic,18,1,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A4,"High-dose, phase 1, 2 doses, 28 days, elderly",B,None,40,Table 2,7,Any,Systemic,18,2,11
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C1,"Low-dose, phase 2, 2 doses, 21 days, adult",C,None,20,Table 3,7,Any,Systemic,100,12,12
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C2,"High-dose, phase 2, 2 doses, 21 days, adult",C,None,40,Table 3,7,Any,Systemic,100,7,7
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B3,"Low-dose, phase 2, 3 doses, 28 days, adult",D,Lower,20,Table 3,7,Any,Systemic,100,10,10
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B4,"High-dose, phase 2, 3 doses, 28 days, adult",D,Standard,40,Table 3,7,Any,Systemic,100,9,9
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C3,"Low-dose, phase 2, 2 doses, 21 days, elderly",E,None,20,Table 3,7,Any,Systemic,100,6,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C4,"High-dose, phase 2, 2 doses, 21 days, elderly",E,None,40,Table 3,7,Any,Systemic,100,3,3
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B5,"Low-dose, phase 2, 3 doses, 28 days, elderly",F,Lower,20,Table 3,7,Any,Systemic,100,12,12
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B6,"High-dose, phase 2, 3 doses, 28 days, elderly",F,Standard,40,Table 3,7,Any,Systemic,100,10,10
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A1,"Low-dose, phase 1, 2 doses, 28 days, adult",A,None,20,Table 2,7,Any,Solicited,24,5,21
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A2,"High-dose, phase 1, 2 doses, 28 days, adult",A,None,40,Table 2,7,Any,Solicited,24,7,29
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A3,"Low-dose, phase 1, 2 doses, 28 days, elderly",B,None,20,Table 2,7,Any,Solicited,18,2,11
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A4,"High-dose, phase 1, 2 doses, 28 days, elderly",B,None,40,Table 2,7,Any,Solicited,18,3,17
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C1,"Low-dose, phase 2, 2 doses, 21 days, adult",C,None,20,Table 3,7,Any,Solicited,100,16,16
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C2,"High-dose, phase 2, 2 doses, 21 days, adult",C,None,40,Table 3,7,Any,Solicited,100,19,19
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B3,"Low-dose, phase 2, 3 doses, 28 days, adult",D,Lower,20,Table 3,7,Any,Solicited,100,22,22
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B4,"High-dose, phase 2, 3 doses, 28 days, adult",D,Standard,40,Table 3,7,Any,Solicited,100,30,30
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C3,"Low-dose, phase 2, 2 doses, 21 days, elderly",E,None,20,Table 3,7,Any,Solicited,100,10,10
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C4,"High-dose, phase 2, 2 doses, 21 days, elderly",E,None,40,Table 3,7,Any,Solicited,100,12,12
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B5,"Low-dose, phase 2, 3 doses, 28 days, elderly",F,Lower,20,Table 3,7,Any,Solicited,100,18,18
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B6,"High-dose, phase 2, 3 doses, 28 days, elderly",F,Standard,40,Table 3,7,Any,Solicited,100,16,16
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A1,"Low-dose, phase 1, 2 doses, 28 days, adult",A,None,20,Table S2,28,Any,Unsolicited,24,1,4
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A2,"High-dose, phase 1, 2 doses, 28 days, adult",A,None,40,Table S2,28,Any,Unsolicited,24,3,13
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A3,"Low-dose, phase 1, 2 doses, 28 days, elderly",B,None,20,Table S2,28,Any,Unsolicited,18,0,0
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A4,"High-dose, phase 1, 2 doses, 28 days, elderly",B,None,40,Table S2,28,Any,Unsolicited,18,1,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C1,"Low-dose, phase 2, 2 doses, 21 days, adult",C,None,20,Table S2,28,Any,Unsolicited,100,2,2
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C2,"High-dose, phase 2, 2 doses, 21 days, adult",C,None,40,Table S2,28,Any,Unsolicited,100,6,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B3,"Low-dose, phase 2, 3 doses, 28 days, adult",D,Lower,20,Table S2,28,Any,Unsolicited,100,0,0
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B4,"High-dose, phase 2, 3 doses, 28 days, adult",D,Standard,40,Table S2,28,Any,Unsolicited,100,6,6
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C3,"Low-dose, phase 2, 2 doses, 21 days, elderly",E,None,20,Table S2,28,Any,Unsolicited,100,1,1
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C4,"High-dose, phase 2, 2 doses, 21 days, elderly",E,None,40,Table S2,28,Any,Unsolicited,100,2,2
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B5,"Low-dose, phase 2, 3 doses, 28 days, elderly",F,Lower,20,Table S2,28,Any,Unsolicited,100,1,1
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B6,"High-dose, phase 2, 3 doses, 28 days, elderly",F,Standard,40,Table S2,28,Any,Unsolicited,100,1,1
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A1,"Low-dose, phase 1, 2 doses, 28 days, adult",A,None,20,Table 2,28,Any,Overall,24,14,58
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A2,"High-dose, phase 1, 2 doses, 28 days, adult",A,None,40,Table 2,28,Any,Overall,24,13,54
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A3,"Low-dose, phase 1, 2 doses, 28 days, elderly",B,None,20,Table 2,28,Any,Overall,18,6,33
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,A4,"High-dose, phase 1, 2 doses, 28 days, elderly",B,None,40,Table 2,28,Any,Overall,18,5,28
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C1,"Low-dose, phase 2, 2 doses, 21 days, adult",C,None,20,Table 3,28,Any,Overall,100,30,30
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C2,"High-dose, phase 2, 2 doses, 21 days, adult",C,None,40,Table 3,28,Any,Overall,100,37,37
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B3,"Low-dose, phase 2, 3 doses, 28 days, adult",D,Lower,20,Table 3,28,Any,Overall,100,31,31
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B4,"High-dose, phase 2, 3 doses, 28 days, adult",D,Standard,40,Table 3,28,Any,Overall,100,41,41
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C3,"Low-dose, phase 2, 2 doses, 21 days, elderly",E,None,20,Table 3,28,Any,Overall,100,19,19
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,C4,"High-dose, phase 2, 2 doses, 21 days, elderly",E,None,40,Table 3,28,Any,Overall,100,26,26
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B5,"Low-dose, phase 2, 3 doses, 28 days, elderly",F,Lower,20,Table 3,28,Any,Overall,100,32,32
118,Meng. F. Y,Signal Transduction and Targeted Therapy,2021,Sf9 cells,Recombinant,West China Hospital,B6,"High-dose, phase 2, 3 doses, 28 days, elderly",F,Standard,40,Table 3,28,Any,Overall,100,28,28
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Partial,Local,120,9,7.5
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Partial,Local,120,4,3.33
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Partial,Local,120,5,4.17
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Partial,Local,120,1,0.83
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Full,Local,119,3,2.52
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Full,Local,120,3,2.5
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Full,Local,117,2,1.71
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Full,Local,117,1,0.85
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Partial,Systemic,120,12,10
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Partial,Systemic,120,7,5.83
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Partial,Systemic,120,7,5.83
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Partial,Systemic,120,12,10
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Full,Systemic,119,11,9.24
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Full,Systemic,120,2,1.67
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Full,Systemic,117,1,0.85
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Full,Systemic,117,2,1.71
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Partial,Solicited,120,16,13.3
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Partial,Solicited,120,9,7.5
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Partial,Solicited,120,10,8.3
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Partial,Solicited,120,13,10.8
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,7,Full,Solicited,119,14,11.8
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,7,Full,Solicited,120,4,3.33
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,7,Full,Solicited,117,3,2.6
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,7,Full,Solicited,117,3,2.6
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,NA,Partial,Unsolicited,120,3,2.5
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,NA,Partial,Unsolicited,120,2,1.7
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,NA,Partial,Unsolicited,120,2,1.7
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,NA,Partial,Unsolicited,120,2,1.7
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,NA,Full,Unsolicited,119,3,2.5
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,NA,Full,Unsolicited,120,2,1.7
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,NA,Full,Unsolicited,117,0,0
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,NA,Full,Unsolicited,117,1,0.85
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,21,Partial,Overall,120,26,21.7
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,21,Partial,Overall,120,23,19.2
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,21,Partial,Overall,120,19,15.8
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,21,Partial,Overall,120,24,20
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, 2 doses, adult",A,Standard,10,Supplementary Table 2,30,Full,Overall,119,24,20.2
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, 2 doses, adult",A,Higher,25,Supplementary Table 2,30,Full,Overall,120,10,8.3
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A3,"10ug, 2 doses, elderly",B,Standard,10,Supplementary Table 2,30,Full,Overall,117,7,6
385,Shu. Y. J,Chinese Medical Journal,2021,V-01,Recombinant,Livzon Mabpharm,A4,"25ug, 2 doses, elderly",B,Higher,25,Supplementary Table 2,30,Full,Overall,117,9,7.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Partial,Local,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Partial,Local,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Partial,Local,24,4,16.67
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Partial,Local,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Partial,Local,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Partial,Local,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Full,Local,24,2,8.33
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Full,Local,24,1,4.35
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Full,Local,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Full,Local,20,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Full,Local,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Full,Local,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Partial,Systemic,24,2,8.33
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Partial,Systemic,24,2,8.33
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Partial,Systemic,24,2,8.33
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Partial,Systemic,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Partial,Systemic,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Partial,Systemic,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Full,Systemic,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Full,Systemic,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Full,Systemic,24,2,8.33
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Full,Systemic,20,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Full,Systemic,24,1,4.17
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Full,Systemic,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,7,Partial,Solicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,7,Partial,Solicited,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,7,Partial,Solicited,24,5,20.8
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,7,Partial,Solicited,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,7,Partial,Solicited,24,1,4.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,7,Partial,Solicited,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,7,Full,Solicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,7,Full,Solicited,24,1,4.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,7,Full,Solicited,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,7,Full,Solicited,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,7,Full,Solicited,24,1,4.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,7,Full,Solicited,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Partial,Unsolicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Partial,Unsolicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Partial,Unsolicited,24,4,16.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Partial,Unsolicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Partial,Unsolicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Partial,Unsolicited,24,2,8.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,NA,Full,Unsolicited,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,NA,Full,Unsolicited,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,NA,Full,Unsolicited,24,0,0
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,NA,Full,Unsolicited,24,1,4.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,NA,Full,Unsolicited,24,1,4.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,NA,Full,Unsolicited,24,4,16.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,30,Partial,Overall,24,12,50
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,30,Partial,Overall,24,13,54.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,30,Partial,Overall,24,16,66.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,30,Partial,Overall,24,11,45.8
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,30,Partial,Overall,24,11,45.8
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,30,Partial,Overall,24,12,50
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A1,"10ug, adult",A,Standard,10,appendix Table S5,30,Full,Overall,24,10,41.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A2,"25ug, adult",A,Higher,25,appendix Table S5,30,Full,Overall,24,7,29.2
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A3,"50ug, adult",A,Higher,50,appendix Table S5,30,Full,Overall,24,8,33.3
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A4,"10ug, elderly",B,Standard,10,appendix Table S5,30,Full,Overall,24,4,16.7
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A5,"25ug, elderly",B,Higher,25,appendix Table S5,30,Full,Overall,24,3,12.5
288,Zhang. J,Emerging Microbes & Infections,2021,V-01,Recombinant,Livzon Mabpharm,A6,"50ug, elderly",B,Higher,50,appendix Table S5,30,Full,Overall,24,7,29.2
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A1,"25ug, 3 doses, phase 1",A,Standard,25,Table 2,7,Any,Local,20,9,45
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A2,"50ug, 3 doses, phase 1",A,Higher,50,Table 2,7,Any,Local,20,12,60
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B1,"25ug, 2 doses, phase 2",B,None,25,Table 3,7,Any,Local,150,17,11
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B2,"50ug, 2 doses, phase 2",B,None,50,Table 3,7,Any,Local,150,9,13
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A3,"25ug, 3 doses, phase 2",C,Standard,25,Table 3,7,Any,Local,150,45,30
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A4,"50ug, 3 doses, phase 2",C,Higher,50,Table 3,7,Any,Local,150,35,23
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A1,"25ug, 3 doses, phase 1",A,Standard,25,Table 2,7,Any,Systemic,20,4,20
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A2,"50ug, 3 doses, phase 1",A,Higher,50,Table 2,7,Any,Systemic,20,5,25
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B1,"25ug, 2 doses, phase 2",B,None,25,Table 3,7,Any,Systemic,150,15,10
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B2,"50ug, 2 doses, phase 2",B,None,50,Table 3,7,Any,Systemic,150,16,11
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A3,"25ug, 3 doses, phase 2",C,Standard,25,Table 3,7,Any,Systemic,150,15,10
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A4,"50ug, 3 doses, phase 2",C,Higher,50,Table 3,7,Any,Systemic,150,13,9
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A1,"25ug, 3 doses, phase 1",A,Standard,25,Table 2,7,Any,Solicited,20,12,60
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A2,"50ug, 3 doses, phase 1",A,Higher,50,Table 2,7,Any,Solicited,20,14,70
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B1,"25ug, 2 doses, phase 2",B,None,25,Table 3,7,Any,Solicited,150,27,18
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B2,"50ug, 2 doses, phase 2",B,None,50,Table 3,7,Any,Solicited,150,32,21
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A3,"25ug, 3 doses, phase 2",C,Standard,25,Table 3,7,Any,Solicited,150,55,37
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A4,"50ug, 3 doses, phase 2",C,Higher,50,Table 3,7,Any,Solicited,150,42,28
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A1,"25ug, 3 doses, phase 1",A,Standard,25,Table 2,NA,Any,Unsolicited,20,6,30
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A2,"50ug, 3 doses, phase 1",A,Higher,50,Table 2,NA,Any,Unsolicited,20,6,30
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B1,"25ug, 2 doses, phase 2",B,None,25,Table 3,NA,Any,Unsolicited,150,5,3
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B2,"50ug, 2 doses, phase 2",B,None,50,Table 3,NA,Any,Unsolicited,150,4,3
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A3,"25ug, 3 doses, phase 2",C,Standard,25,Table 3,NA,Any,Unsolicited,150,7,5
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A4,"50ug, 3 doses, phase 2",C,Higher,50,Table 3,NA,Any,Unsolicited,150,4,3
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A1,"25ug, 3 doses, phase 1",A,Standard,25,Table 2,30,Any,Overall,20,14,70
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A2,"50ug, 3 doses, phase 1",A,Higher,50,Table 2,31,Any,Overall,20,18,90
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B1,"25ug, 2 doses, phase 2",B,None,25,Table 3,32,Any,Overall,150,43,29
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,B2,"50ug, 2 doses, phase 2",B,None,50,Table 3,33,Any,Overall,150,50,33
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A3,"25ug, 3 doses, phase 2",C,Standard,25,Table 3,34,Any,Overall,150,72,48
346,Yang. S,Lancet ID,2021,ZF2001,Recombinant,Anhui Zhifei,A4,"50ug, 3 doses, phase 2",C,Higher,50,Table 3,35,Any,Overall,150,65,43
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 2,7,Any,Local,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 2,7,Any,Local,24,24,100
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 2,7,Any,Local,24,18,75
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 2,7,Any,Local,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 3,14,Any,Local,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 3,14,Any,Local,24,24,100
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 3,14,Any,Local,24,18,75
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 3,14,Any,Local,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 2,7,Any,Systemic,24,17,71
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 2,7,Any,Systemic,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 2,7,Any,Systemic,24,4,17
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 2,7,Any,Systemic,24,18,75
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 3,14,Any,Systemic,24,17,71
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 3,14,Any,Systemic,24,22,92
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 3,14,Any,Systemic,24,9,38
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 3,14,Any,Systemic,24,19,79
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 2,7,Any,Solicited,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 2,7,Any,Solicited,24,24,100
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 2,7,Any,Solicited,24,20,83
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 2,7,Any,Solicited,24,22,92
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 3,14,Any,Solicited,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 3,14,Any,Solicited,24,24,100
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 3,14,Any,Solicited,24,21,88
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 3,14,Any,Solicited,24,23,96
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 2,50,Any,Unsolicited,24,9,38
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 2,50,Any,Unsolicited,24,10,42
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 2,50,Any,Unsolicited,24,4,17
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 2,50,Any,Unsolicited,24,9,38
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult",A,Lower,10,Table 3,50,Any,Unsolicited,24,9,38
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A2,"30ug, adult",A,Standard,30,Table 3,50,Any,Unsolicited,24,10,42
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A3,"10ug, elderly",B,Lower,10,Table 3,50,Any,Unsolicited,24,4,17
218,Li. J,Nature Medicine,2021,BNT162b1,mRNA,Pfizer/BioNTech,A4,"30ug, elderly",B,Standard,30,Table 3,50,Any,Unsolicited,24,9,38
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,10ug,A,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,30ug,A,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,100ug,A,Higher,100,Figure 2,7,Partial,Local,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,10ug,A,Lower,10,Figure 2,7,Full,Local,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,30ug,A,Standard,30,Figure 2,7,Full,Local,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,10ug,A,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,30ug,A,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,100ug,A,Higher,100,Figure 3,7,Partial,Systemic,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,10ug,A,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,30ug,A,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,10ug,A,Lower,10,Text,7,Any,Overall,12,6,50
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,30ug,A,Standard,30,Text,7,Any,Overall,12,6,50
10,Mulligan. M. J,Nature,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,100ug,A,Higher,100,Text,7,Any,Overall,12,7,58.3
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 2,7,Partial,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 2,7,Full,Local,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 3,7,Partial,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A1,"10ug, adult, BNT162b1",A,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A2,"20ug, adult, BNT162b1",A,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A3,"30ug, adult, BNT162b1",A,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A4,"10ug, elderly, BNT162b1",B,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A5,"20ug, elderly, BNT162b1",B,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,A6,"30ug, elderly, BNT162b1",B,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B1,"10ug, adult, BNT162b2",C,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B2,"20ug, adult, BNT162b2",C,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B3,"30ug, adult, BNT162b2",C,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B4,"10ug, elderly, BNT162b2",D,Lower,10,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B5,"20ug, elderly, BNT162b2",D,Lower,20,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b1,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
18,Walsh. E. E,New England Journal of Medicine,2020,BNT162b2,mRNA,Pfizer/BioNTech,B6,"30ug, elderly, BNT162b2",D,Standard,30,Figure 3,7,Full,Systemic,12,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A1,10ug,A,Standard,10,Figure S1,7,Partial,Local,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,20ug,A,Higher,20,Figure S1,7,Partial,Local,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,30ug,A,Higher,30,Figure S1,7,Partial,Local,4,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A1,10ug,A,Standard,10,Figure S1,7,Full,Local,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,20ug,A,Higher,20,Figure S1,7,Full,Local,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,30ug,A,Higher,30,Figure S1,7,Full,Local,4,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A1,10ug,A,Standard,10,Figure S1,7,Partial,Systemic,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,20ug,A,Higher,20,Figure S1,7,Partial,Systemic,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,30ug,A,Higher,30,Figure S1,7,Partial,Systemic,4,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A1,10ug,A,Standard,10,Figure S1,7,Full,Systemic,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,20ug,A,Higher,20,Figure S1,7,Full,Systemic,16,NA,NA
2597,Walter. E. B,New England Journal of Medicine,2021,BNT162b2,mRNA,Pfizer/BioNTech,A2,30ug,A,Higher,30,Figure S1,7,Full,Systemic,4,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A1,2ug group,A,Lower,2,"appendix Table 3, 4a, figure 2",7,Partial,Local,38,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A2,4ug group,A,Lower,4,"appendix Table 3, 4a, figure 2",7,Partial,Local,40,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A3,6ug group,A,Lower,6,"appendix Table 3, 4a, figure 2",7,Partial,Local,40,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A4,8ug group,A,Lower,8,"appendix Table 3, 4a, figure 2",7,Partial,Local,38,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A5,12ug group,A,Standard,12,"appendix Table 3, 4a, figure 2",7,Partial,Local,24,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A1,2ug group,A,Lower,2,"appendix Table 3, 4b, figure 2",7,Full,Local,36,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A2,4ug group,A,Lower,4,"appendix Table 3, 4b, figure 2",7,Full,Local,37,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A3,6ug group,A,Lower,6,"appendix Table 3, 4b, figure 2",7,Full,Local,37,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A4,8ug group,A,Lower,8,"appendix Table 3, 4b, figure 2",7,Full,Local,35,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A5,12ug group,A,Standard,12,"appendix Table 3, 4b, figure 2",7,Full,Local,23,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A1,2ug group,A,Lower,2,"appendix Table 3, 4a, figure 2",7,Partial,Systemic,38,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A2,4ug group,A,Lower,4,"appendix Table 3, 4a, figure 2",7,Partial,Systemic,40,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A3,6ug group,A,Lower,6,"appendix Table 3, 4a, figure 2",7,Partial,Systemic,40,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A4,8ug group,A,Lower,8,"appendix Table 3, 4a, figure 2",7,Partial,Systemic,38,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A5,12ug group,A,Standard,12,"appendix Table 3, 4a, figure 2",7,Partial,Systemic,24,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A1,2ug group,A,Lower,2,"appendix Table 3, 4b, figure 2",7,Full,Systemic,36,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A2,4ug group,A,Lower,4,"appendix Table 3, 4b, figure 2",7,Full,Systemic,37,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A3,6ug group,A,Lower,6,"appendix Table 3, 4b, figure 2",7,Full,Systemic,37,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A4,8ug group,A,Lower,8,"appendix Table 3, 4b, figure 2",7,Full,Systemic,35,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A5,12ug group,A,Standard,12,"appendix Table 3, 4b, figure 2",7,Full,Systemic,23,NA,NA
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A1,2ug group,A,Lower,2,"appendix Table 3, 4b, figure 2",28,Any,Unsolicited,47,7,14.9
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A2,4ug group,A,Lower,4,"appendix Table 3, 4b, figure 2",28,Any,Unsolicited,48,19,39.6
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A3,6ug group,A,Lower,6,"appendix Table 3, 4b, figure 2",28,Any,Unsolicited,46,15,32.6
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A4,8ug group,A,Lower,8,"appendix Table 3, 4b, figure 2",28,Any,Unsolicited,44,18,40.9
754,Kremsner. P. G,Wien Klin Wochenschr,2021,CVnCoV,mRNA,Curevac,A5,12ug group,A,Standard,12,"appendix Table 3, 4b, figure 2",28,Any,Unsolicited,28,12,42.9
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 56to70",A,Lower,25,Table S2,7,Partial,Local,10,5,50
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 70 and above",B,Lower,25,Table S2,7,Partial,Local,10,6,60
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A3,"High-dose, 56to70",A,Standard,100,Table S2,7,Partial,Local,10,8,80
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A4,"High-dose, 70 and above",B,Standard,100,Table S2,7,Partial,Local,10,8,80
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 56to70",A,Lower,25,Table S2,7,Full,Local,10,6,60
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 70 and above",B,Lower,25,Table S2,7,Full,Local,10,7,70
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A3,"High-dose, 56to70",A,Standard,100,Table S2,7,Full,Local,9,8,88.9
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A4,"High-dose, 70 and above",B,Standard,100,Table S2,7,Full,Local,10,10,100
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 56to70",A,Lower,25,Table S2,7,Partial,Systemic,10,5,50
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 70 and above",B,Lower,25,Table S2,7,Partial,Systemic,10,5,50
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A3,"High-dose, 56to70",A,Standard,100,Table S2,7,Partial,Systemic,10,3,30
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A4,"High-dose, 70 and above",B,Standard,100,Table S2,7,Partial,Systemic,10,3,30
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 56to70",A,Lower,25,Table S2,7,Full,Systemic,10,7,70
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 70 and above",B,Lower,25,Table S2,7,Full,Systemic,10,3,30
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A3,"High-dose, 56to70",A,Standard,100,Table S2,7,Full,Systemic,9,8,88.9
12,Anderson .E. J,The new england journal o f medicine,2020,mRNA-1273,mRNA,Moderna,A4,"High-dose, 70 and above",B,Standard,100,Table S2,7,Full,Systemic,10,7,70
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 18to55",A,Lower,50,Table S2,7,Partial,Local,100,73,73
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"High-dose, 18to55",A,Standard,100,Table S2,7,Partial,Local,100,87,87
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 18to55",A,Lower,50,Table S2,7,Full,Local,97,78,80
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 18to55",A,Standard,100,Table S2,7,Full,Local,99,89,90
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Partial,Local,100,58,58
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 55 and above",B,Standard,100,Table S2,7,Partial,Local,100,81,81
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Full,Local,100,78,80
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 55 and above",B,Standard,100,Table S2,7,Full,Local,100,81,82
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 18to55",A,Lower,50,Table S2,7,Partial,Systemic,100,46,46
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"High-dose, 18to55",A,Standard,100,Table S2,7,Partial,Systemic,100,52,52
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 18to55",A,Lower,50,Table S2,7,Full,Systemic,97,69,71
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 18to55",A,Standard,100,Table S2,7,Full,Systemic,99,89,79
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Partial,Systemic,100,37,37
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 55 and above",B,Standard,100,Table S2,7,Partial,Systemic,100,37,37
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Full,Systemic,100,66,67
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 55 and above",B,Standard,100,Table S2,7,Full,Systemic,100,75,76
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 18to55",A,Lower,50,Table S2,7,Partial,Solicited,100,79,79
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"High-dose, 18to55",A,Standard,100,Table S2,7,Partial,Solicited,100,91,91
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 18to55",A,Lower,50,Table S2,7,Full,Solicited,97,86,89
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 18to55",A,Standard,100,Table S2,7,Full,Solicited,99,92,93
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A1,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Partial,Solicited,100,63,63
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A2,"Low-dose, 55 and above",B,Standard,100,Table S2,7,Partial,Solicited,100,85,85
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A3,"Low-dose, 55 and above",B,Lower,50,Table S2,7,Full,Solicited,98,85,87
233,Chu. L,Vaccine,2021,mRNA-1273,mRNA,Moderna,A4,"High-dose, 55 and above",B,Standard,100,Table S2,7,Full,Solicited,99,86,87
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A1,25ug,A,Lower,25,appendix Table S2,7,Partial,Local,15,10,66.7
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A2,100ug,A,Standard,100,appendix Table S2,7,Partial,Local,15,13,86.6
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A3,250ug,A,Higher,250,appendix Table S2,7,Partial,Local,15,15,100
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A1,25ug,A,Lower,25,appendix Table S2,7,Full,Local,13,10,76.9
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A2,100ug,A,Standard,100,appendix Table S2,7,Full,Local,15,15,100
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A3,250ug,A,Higher,250,appendix Table S2,7,Full,Local,14,14,100
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A1,25ug,A,Lower,25,appendix Table S2,7,Partial,Systemic,15,5,33.3
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A2,100ug,A,Standard,100,appendix Table S2,7,Partial,Systemic,15,10,66.7
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A3,250ug,A,Higher,250,appendix Table S2,7,Partial,Systemic,15,8,53.4
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A1,25ug,A,Lower,25,appendix Table S2,7,Full,Systemic,13,7,53.9
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A2,100ug,A,Standard,100,appendix Table S2,7,Full,Systemic,15,15,100
19,Jackson. L. A,New England Journal of Medicine,2020,mRNA-1273,mRNA,Moderna,A3,250ug,A,Higher,250,appendix Table S2,7,Full,Systemic,14,11,78.6
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A1/B1,NA,A,Standard,5,appendix Table S3,7,Partial,Local,162,104,64.2
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A2/B2,NA,A,Higher,10,appendix Table S3,7,Partial,Local,158,123,77.5
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A3,NA,B,Standard,5,appendix Table S3,7,Partial,Local,161,66,41
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A4,NA,B,Higher,10,appendix Table S3,7,Partial,Local,161,68,42.2
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A1/B1,NA,A,Standard,5,appendix Figure S3,7,Full,Local,80,53,66.4
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A2/B2,NA,A,Higher,10,appendix Figure S3,7,Full,Local,80,58,73
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A1/B1,NA,A,Standard,5,appendix Table S3,7,Partial,Systemic,162,105,64.8
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A2/B2,NA,A,Higher,10,appendix Table S3,7,Partial,Systemic,158,132,83.5
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A3,NA,B,Standard,5,appendix Table S3,7,Partial,Systemic,161,74,46
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A4,NA,B,Higher,10,appendix Table S3,7,Partial,Systemic,161,88,54.7
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A1/B1,NA,A,Standard,5,appendix Figure S3,7,Full,Systemic,80,47,58.4
16,Sadoff. J,New England Journal of Medicine,2021,Ad26.COV2.S,Vector,Janssen,A2/B2,NA,A,Higher,10,appendix Figure S3,7,Full,Systemic,80,55,69
526,Wu. S,Lancet ID,2021,Ad5-nCoV,Vector,AMMS,A1,1Dium,A,None,5,appendix Table S1,7,Full,Solicited,26,19,73.1
526,Wu. S,Lancet ID,2021,Ad5-nCoV,Vector,AMMS,A2,2Dium,A,None,10,appendix Table S1,7,Full,Solicited,26,15,57.7
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,Low dose,A,Standard,5,Table 2,7,Full,Solicited,36,30,83
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Middle dose,A,Higher,10,Table 2,7,Full,Solicited,36,30,83
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A3,High dose,A,Higher,15,Table 2,7,Full,Solicited,36,27,75
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,Low dose,A,Standard,5,Table 2,28,Full,Overall,36,31,86
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Middle dose,A,Higher,10,Table 2,28,Full,Overall,36,30,83
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A3,High dose,A,Higher,15,Table 2,28,Full,Overall,36,27,75
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,Low dose,A,Standard,5,Table 2,7,Full,Local,36,NA,NA
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Middle dose,A,Higher,10,Table 2,7,Full,Local,36,NA,NA
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A3,High dose,A,Higher,15,Table 2,7,Full,Local,36,NA,NA
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,Low dose,A,Standard,5,Table 2,7,Full,Systemic,36,NA,NA
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Middle dose,A,Higher,10,Table 2,7,Full,Systemic,36,NA,NA
17,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A3,High dose,A,Higher,15,Table 2,7,Full,Systemic,36,NA,NA
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,High dose,A,Higher,10,Table 2,14,Full,Solicited,253,183,72
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Low dose,A,Standard,5,Table 2,14,Full,Solicited,129,96,74
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,High dose,A,Higher,10,Table 2,14,Full,Unsolicited,253,19,8
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Low dose,A,Standard,5,Table 2,14,Full,Unsolicited,129,7,5
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,High dose,A,Higher,10,Table 2,28,Full,Overall,253,196,77
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Low dose,A,Standard,5,Table 2,28,Full,Overall,129,98,76
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,High dose,A,Higher,10,Table 2,14,Full,Local,253,NA,NA
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Low dose,A,Standard,5,Table 2,14,Full,Local,129,NA,NA
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A1,High dose,A,Higher,10,Table 2,14,Full,Systemic,253,NA,NA
3,Zhu. F,Lancet,2020,Ad5-nCoV,Vector,CanSino,A2,Low dose,A,Standard,5,Table 2,14,Full,Systemic,129,NA,NA
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Partial,Local,100,17,17
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Partial,Local,100,21,21
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Full,Local,100,18,18
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Full,Local,100,17,17
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Partial,Systemic,100,10,10
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Partial,Systemic,100,6,6
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Full,Systemic,100,9,9
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Full,Systemic,100,3,3
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Partial,Solicited,100,23,23
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Partial,Solicited,100,24,24
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,14,Full,Solicited,100,22,22
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,14,Full,Solicited,100,19,19
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,28,Partial,Unsolicited,100,5,5
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,28,Partial,Unsolicited,100,2,2
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A1,"Middle dose, old cohort",A,Higher,10,Supplementary Table 4,28,Full,Unsolicited,100,0,0
2431,Zhu. F,Clinical infectious disease,2021,Ad5-nCoV,Vector,CanSino,A2,"Low dose, old cohort",A,Standard,5,Supplementary Table 4,28,Full,Unsolicited,100,1,1
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A1,1mg dose group,A,Standard,1,Figure 2,56,Partial,Local,20,2,10
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A2,2mg dose group,A,Higher,2,Figure 2,56,Partial,Local,20,1,5
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A1,1mg dose group,A,Standard,1,Figure 2,56,Full,Local,20,2,10
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A2,2mg dose group,A,Higher,2,Figure 2,56,Full,Local,20,0,0
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A1,1mg dose group,A,Standard,1,Figure 2,56,Partial,Systemic,20,0,0
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A2,2mg dose group,A,Higher,2,Figure 2,56,Partial,Systemic,20,1,5
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A1,1mg dose group,A,Standard,1,Figure 2,56,Full,Systemic,20,0,0
837,Tebas. P,EClinicalMedicine,2021,INO-4880,DNA,Inovio,A2,2mg dose group,A,Higher,2,Figure 2,56,Full,Systemic,20,0,0
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,A1,"1mg, needle",A,None,1,Figure 2,7,Any,Local,12,1,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,A2,"2mg, needle",A,None,2,Figure 2,7,Any,Local,12,1,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,B1,"1mg, needle free",B,None,1,Figure 2,7,Any,Local,12,1,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,B2,"2mg, needle free",B,None,2,Figure 2,7,Any,Local,12,2,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,A1,"1mg, needle",A,None,1,Figure 2,7,Any,Systemic,12,1,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,A2,"2mg, needle",A,None,2,Figure 2,7,Any,Systemic,12,1,8.3
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,B1,"1mg, needle free",B,None,1,Figure 2,7,Any,Systemic,12,0,0
779,Momin. T,EClinicalMedicine,2021,ZyCoV-D,DNA,Zydus Cadila,B2,"2mg, needle free",B,None,2,Figure 2,7,Any,Systemic,12,0,0
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A1,NA,A,Standard,3.75,Figure 2,7,Partial,Local,20,20,100
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A2,NA,A,Higher,7.5,Figure 2,7,Partial,Local,20,16,80
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A3,NA,A,Higher,15,Figure 2,7,Partial,Local,20,17,85
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B1,NA,B,None,3.75,Figure 2,7,Partial,Local,20,17,85
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B2,NA,B,None,7.5,Figure 2,7,Partial,Local,20,16,80
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B3,NA,B,None,15,Figure 2,7,Partial,Local,20,16,80
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A1,NA,A,Standard,3.75,Figure 2,7,Full,Local,19,19,100
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A2,NA,A,Higher,7.5,Figure 2,7,Full,Local,20,19,95
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A3,NA,A,Higher,15,Figure 2,7,Full,Local,20,16,80
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B1,NA,B,None,3.75,Figure 2,7,Full,Local,20,15,75
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B2,NA,B,None,7.5,Figure 2,7,Full,Local,20,14,70
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B3,NA,B,None,15,Figure 2,7,Full,Local,19,14,73.7
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A1,NA,A,Standard,3.75,Figure 2,7,Partial,Systemic,20,10,50
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A2,NA,A,Higher,7.5,Figure 2,7,Partial,Systemic,20,6,30
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A3,NA,A,Higher,15,Figure 2,7,Partial,Systemic,20,12,60
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B1,NA,B,None,3.75,Figure 2,7,Partial,Systemic,20,13,65
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B2,NA,B,None,7.5,Figure 2,7,Partial,Systemic,20,10,50
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B3,NA,B,None,15,Figure 2,7,Partial,Systemic,20,7,35
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A1,NA,A,Standard,3.75,Figure 2,7,Full,Systemic,19,16,84.2
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A2,NA,A,Higher,7.5,Figure 2,7,Full,Systemic,20,18,90
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A3,NA,A,Higher,15,Figure 2,7,Full,Systemic,20,15,75
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B1,NA,B,None,3.75,Figure 2,7,Full,Systemic,20,9,45
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B2,NA,B,None,7.5,Figure 2,7,Full,Systemic,20,7,35
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B3,NA,B,None,15,Figure 2,7,Full,Systemic,19,9,47.4
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B1,NA,B,None,3.75,Table S8-10,21,Full,Unsolicited,20,9,45
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B2,NA,B,None,7.5,Table S8-10,21,Full,Unsolicited,20,11,55
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,B3,NA,B,None,15,Table S8-10,21,Full,Unsolicited,20,6,30
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A1,NA,A,Standard,3.75,Table S8-10,21,Full,Unsolicited,20,8,40
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A2,NA,A,Higher,7.5,Table S8-10,21,Full,Unsolicited,20,7,35
303,Ward. B. J,Nature Medicine,2021,Plant-based VLP,Virus-like particle,Medicago,A3,NA,A,Higher,15,Table S8-10,21,Full,Unsolicited,20,11,55